Abstract
Patients’ responses to items on a questionnaire are frequently used to assess treatment effects in clinical trials. In this paper, we will use the Unified Parkinson’s Disease Rating Scale to address a common question of whether it is more powerful to compare treatments based on the total scores of part II (questions 5–17 on the questionnaire) and part III (questions 18–31) combined or the individual component scores (either part II or part III). We will explore the relationships among the powers associated with the various test statistics and display the relationships using graphs. As an illustration, we will apply our findings to help decide on the primary endpoint for a clinical trial in Parkinson’s disease patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Reference
Fahn S, Elton RL, and Members of the UPDRS Development Committee. Unified Parkinson’s Disease Rating Scale in Recent Developments in Parkinson’s Disease. Volume II. Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Florham Park, NJ: MacMillan Healthcare Information; 1987:153–163, 293–304.
O’Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics. December 1984;40:1079–1087.
Food and Drug Administration. Guidance for Industry: Clinical Studies Section of Labeling for Prescription Drugs and Biologies—Content and Format. Draft guidance. Rockville, MD: Food and Drug Administration; May 2001.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chang, W.H., Chuang-Stein, C. Component Scores, or Total Scores over Components?. Ther Innov Regul Sci 36, 557–564 (2002). https://doi.org/10.1177/009286150203600310
Published:
Issue Date:
DOI: https://doi.org/10.1177/009286150203600310